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ABSTRACT 
Aortic stenosis (AS) and regurgitation (AR) may be treated with surgical aortic 
valve replacement (SAVR), transcatheter AVR (TAVR), or medical therapy (MT).  Data 
are lacking regarding usage and cost of SAVR, TAVR, and MT for patients hospitalized 
with aortic valve disease.  From the Nationwide Readmissions Database, we determined 
utilization and cost trends for SAVR, TAVR, and MT in patients with aortic valve disease 
admitted 2012-2016 for valve replacement, heart failure, unstable angina, non-ST-
elevation myocardial infarction, or syncope.  From 2012 through 2016, there was a 
48.1% increase in the number of patients hospitalized for aortic valve disease annually.  
Overall, 19.9%, 6.7%, and 73.4% of patients received SAVR, TAVR, and MT, 
respectively.  SAVR decreased from 21.9% in 2012 to 18.5% in 2016; TAVR increased 
from 2.6% to 12.5%; and MT decreased from 75.5% to 69.0%.  In multivariable analysis, 
likelihood of TAVR relative to SAVR increased 4.57-fold (95% confidence interval 4.21-
4.97) with TAVR increasing at the expense of both SAVR and MT.  The average 6-
month inpatient costs were $59,743 for SAVR, $64,395 for TAVR, and $23,460 for MT.  
TAVR IA costs decreased over time to become similar to SAVR costs by 2016.  The 
TAVR increase was distributed inequitably, with certain patients more likely to receive 
TAVR and certain hospitals more likely to provide TAVR.  Aggregate costs were higher 
for TAVR than SAVR and were significantly more expensive than MT alone.  With the 
  
 
expected expansion of indications, equitable and affordable access to TAVR must be 
addressed to minimize disparities and to optimize patient outcomes.   
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CHAPTER 1:  INTRODUCTION 
Therapies for Aortic Valve Disease 
Aortic stenosis (AS) and aortic regurgitation (AR) may be treated with one of 
three strategies:  surgical aortic valve replacement (SAVR), transcatheter aortic valve 
replacement (TAVR), or medical therapy (MT).  The United States (US) Food and Drug 
Administration (FDA) approved TAVR for the treatment of severe AS in inoperable 
patients2 in November 2011, high-risk patients 3,4 in October 2012, and intermediate-
risk5,6 patients in August 2016.  Small numbers of TAVR procedures may performed off-
label for patients with severe AR7 or mixed AS and AR8.  However, definitive data are 
lacking regarding the actual usage of SAVR, TAVR, and MT for patients hospitalized 
with aortic valve disease and the characteristics of the patients and hospitals associated 
with each of these therapies.   
 
Rates of SAVR, TAVR, and MT 
Prior studies demonstrate an increase in the number of SAVR and TAVR 
procedures performed in the US over time.  Medicare data for patients over age 65 show 
an increase in hospitalizations for SAVR from 24,568 in 1989 to 31,380 in 20119, and 
TAVR procedure volumes increased from 4,627 procedures at 198 centers in 2012 to 
24,808 procedures at 418 centers in 201510.  The relative usage of SAVR and TAVR is 
also evolving.  In the Society of Thoracic Surgeons database, the absolute number of 
TAVR procedures surpassed SAVR procedures in 201611, but the overall rate of SAVR 
has remained relatively stable12.  Little is known about trends in patients receiving MT.   
To address these gaps in knowledge, we sought to characterize temporal trends 
in the use of SAVR, TAVR, or MT following admission to US hospitals with a primary or 
secondary diagnosis of AS or AR from 2012 through 2016.  We hypothesized that the 




urban teaching hospitals, while the number of patients receiving MT and the number of 
high-risk patients undergoing SAVR have decreased. 
 
Costs of SAVR, TAVR, and MT 
Data also are lacking regarding the relative costs of SAVR, TAVR, and MT for 
patients hospitalized with aortic valve disease.  Prior studies examining the costs of AS 
care have yielded varying results.  In general, TAVR has been associated with increased 
up-front costs but decreased post-procedural resource utilization in comparison to SAVR 
and MT, and follow-up costs have correlated with patients’ procedural risk level.  Cost 
effectiveness estimates fluctuate widely, particularly as a result of varying costs in 
different healthcare systems13.  In sum, the actual costs of SAVR, TAVR, and MT remain 
poorly understood.   
We examined 6-month total inpatient healthcare expenditures for patients with 
aortic valve disease admitted from 2012-2016 for valve replacement, heart failure, 
unstable angina, non-ST-elevation myocardial infarction, or syncope.  We also 
performed multivariable and subgroup analyses to investigate the associations of 
treatment strategy with costs and inpatient days.  In contrast to prior studies, our 
inclusive nationwide economic approach captured the largest patient population to date 
across diverse health systems and with numerous payment sources.  Furthermore, 
unlike prior analysis, we sought to compare the costs of SAVR and TAVR to MT.  Lastly, 
we report 5-year temporal trends in the economics of aortic valve disease care.  This 
novel information may facilitate future interventions to address disparities in costs and 





CHAPTER 2:  METHODS 
Data 
 Data were obtained from the Nationwide Readmissions Database (NRD), the 
largest, all-payer inpatient care database of the Agency for Healthcare Research and 
Quality’s (AHRQ’s) Healthcare Cost and Utilization Project (HCUP) containing an 
approximately 20% stratified sample of discharges from all hospitals in 27 US states14.  
Data from the NRD and its sister database, the National Inpatient Sample (NIS), have 
been used for multiple prior studies evaluating patients who have undergone TAVR15-18.  
From the NRD, we obtained de-identified discharge-level data files from 2012 through 
2016. Each discharge record includes patient demographics and comorbidities, hospital 
characteristics, expected payment source, and discharge status.  The NRD also collects 
primary and secondary (up to 35) discharge diagnoses and primary and secondary (up 
to 15) procedures based on the International Classification of Diseases, Clinical 
Modification codes (ICD-9-CM for 2012 through 2015 third quarter, ICD-10-CM for 2015 
fourth quarter through 2016). From 2012 through 2016, participation in the HCUP NRD 
increased from 18 to 27 states. We linked the NRD with cost-to-charge ratio files from 
the Healthcare Cost Report Information System19 to convert total charges to total costs.  
We adjusted total costs for each year to 2016 US dollars using the medical care 
consumer price index20.   
 
Study Populations 
Patient linkage numbers facilitate tracking individual patients across multiple 
hospitalizations and between participating states, however, because each annual NRD 
data set is independent, individual patients cannot be tracked between years.  




disease and discharged from January 1 through June 30 in each calendar year, allowing 
for 6 months of follow-up for every patient.  
In the analysis of the rates of SAVR, TAVR, and MT, the index admission (IA) 
was defined as the patient's first discharge with a primary or secondary diagnosis of non-
rheumatic aortic valve stenosis or regurgitation, which was identified based upon ICD-9-
CM (424.1) and ICD-10-CM (I35.0, I35.1, I35.2, I35.8, I35.9) codes, plus at least one of 
the following procedures or diagnoses:  SAVR (ICD-9-CM 35.21, 35.22; ICD-10-CM 
02RF07Z, 02RF08Z, 02RF0JZ, 02RF0KZ), TAVR (ICD-9-CM 35.05, 35.06; ICD-10-CM 
02RF37H, 02RF37Z, 02RF38H, 02RF38Z, 02RF3JH, 02RF3JZ, 02RF3KH, 02RF3KZ), 
congestive heart failure (CHF; ICD-9-CM 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 
428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43; ICD-10-CM I50.1, 
I50.20, I50.21, I50.22, I50.23, I50.30, I50.31, I50.32, I50.33, I50,40, I50.41, I50.42, 
I50.43), unstable angina (UA; ICD-9-CM 411.1; ICD-10-CM I20.0), non-ST-elevation 
myocardial infarction (NSTEMI; ICD-9-CM 410.7 410.70 410.71 410.72; ICD-10-CM 
I21.4) or syncope (ICD-9-CM 780.2; ICD-10-CM R55) as any of up to 15 procedures or 
any of up to 35 diagnoses.  
 Treatment strategy was classified as SAVR, TAVR, or MT. ICD-CM codes were 
used to identify patients undergoing SAVR and TAVR during the IA or within 180 days of 
the IA discharge date.  Patients not undergoing SAVR or TAVR within 180 days of IA 
discharge were categorized as receiving MT.  
In the analysis of costs, inpatient days, and admissions, IA was defined as a 
patient's first discharge during which AS/AR (ICD-9-CM 424.1; ICD-10-CM I35.0, I35.1, 
I35.2, I35.8, I35.9) was a primary or secondary diagnosis, and SAVR (ICD-9-CM 35.21, 
35.22; ICD-10-CM 02RF07Z, 02RF08Z, 02RF0JZ, 02RF0KZ) or TAVR (ICD-9-CM 
35.05, 35.06; ICD-10-CM 02RF37H, 02RF37Z, 02RF38H, 02RF38Z, 02RF3JH, 




first discharge with either a primary diagnosis of AS/AR plus a secondary diagnosis of 
symptoms or a primary diagnosis of symptoms plus a secondary diagnosis of AS/AR 
with no SAVR or TAVR performed during the calendar year.  Symptoms included 
congestive heart failure (CHF; ICD-9-CM 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 
428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43; ICD-10-CM I50.1, 
I50.20, I50.21, I50.22, I50.23, I50.30, I50.31, I50.32, I50.33, I50,40, I50.41, I50.42, 
I50.43), unstable angina (UA; ICD-9-CM 411.1; ICD-10-CM I20.0), non-ST-elevation 
myocardial infarction (NSTEMI; ICD-9-CM 410.7 410.70 410.71 410.72; ICD-10-CM 
I21.4) or syncope (ICD-9-CM 780.2; ICD-10-CM R55).  Admissions were excluded from 
IA if patients died prior to discharge.  
We excluded 2011 data because TAVR was not approved in the United States 
until November of that year; only 21 patients in the NRD underwent TAVR in 2011.  This 
study was exempt from the requirements of the Institutional Review Board at the 
University of Nebraska Medical Center because the NRD contains no patient-identifiable 
information.   
 
Variables 
 In the analysis of the rates of SAVR, TAVR, and MT, the primary independent 
variable was treatment year.  Among explanatory variables, we assessed for patient age 
(≤64, 65-74, 75-84, ≥85 years), sex, two health status variables constructed by NRD 
(severity of illness and risk of mortality) and the number of comorbid diagnoses reported 
during IA (1-10, 11-15, 16-20, 21-35).  Age and number of diagnoses were converted to 
categorical variables because their relationships with SAVR, TAVR, and MT were highly 
non-linear, even with log transformation; all other predictors were presented as 
categorical variables by the NRD.  Using 3M All Patient Refined Diagnosis Related 




comorbidity or complications), moderate, major, and extreme loss of function. Similarly, 
risk of mortality is categorized into minor, moderate, major, and extreme likelihood of 
dying.     
 We also assessed both for patient insurance status (Medicare, Medicaid, private, 
self-pay, no charge/other) and neighborhood median household income as a proxy of 
patient socioeconomic status, and county population density as a proxy of urban/rural 
location. Quartiles of neighborhood median household income for patient ZIP code were 
defined each year (e.g., in 2016, the quartiles were defined as $1-42,999, $43,000-
53,999, $54,000-70,999, and $71,000 or more). NRD also included county population 
density classification constructed by National Center for Health Statistics (less than 
249,999, 250,000-999,999, fringe counties of ≥1 million, central counties of ≥1 million 
population).  
 For hospital characteristics, we assessed for ownership (for-profit private; not-for-
profit private; government, non-federal), size (small, medium, large per NRD criteria by 
region and teaching status23), and status as an urban teaching hospital (urban non-
teaching, rural, urban teaching,).    
In the analysis of costs, inpatient days, and admissions, the primary independent 
variable was treatment strategy (SAVR, TAVR, or MT, as defined in the Methods above).  
Explanatory variables were similar to those studied in the first analysis but also included 
Charlson comorbidity index24, constructed from ICD-9-CM25 or ICD-10-CM26 codes, as 
well as number of inpatient procedures (e.g. echocardiogram, coronary artery bypass 
surgery, percutaneous coronary intervention).  Age, Charlson comorbidity index, and 
number of procedures were converted to categorical variables because their 
relationships with 3 outcomes were highly non-linear, even with log transformation; all 
other predictors were presented as categorical variables by the NRD.  We studied 3 




aggregate for all admissions as well as separately for IA only and for 6-month unplanned 
readmissions only, using the NRD variable for non-elective admissions.  We also 
assessed 5-year temporal trends for these outcomes. 
 
Statistical Analysis 
 Using Pearson Chi-squared tests, we examined systematic differences in the 
rates of SAVR, TAVR, and MT between 2012 and 2016, and assessed for systematic 
differences between treatment strategy and each explanatory variable.  
For multivariate analysis, we employed a multinomial logistic (MNL) model to evaluate 
the factors associated with treatment strategy.  We tested two MNL models: the first 
model used SAVR as the base outcome (which generated two sets of coefficient 
estimates, TAVR versus SAVR, and MT versus SAVR), and the second model used MT 
as the base outcome (which generated SAVR versus MT and TAVR versus MT).  
Coefficients of MNL models were converted to relative risk ratios (RRR)27,28.   
We performed three sensitivity analyses to confirm the validity of our methodology. First, 
we defined IA using just non-rheumatic AS or AR as any admission diagnosis without 
considering other conditions (i.e., SAVR, TAVR, CHF, UA, NSTEMI, or syncope). 
Second, we performed the analysis defining IA using only a primary diagnosis of AS or 
AR. Third, we repeated the analysis using 3-month and 9-month follow-up periods by 
allowing IA from January through September or January through March respectively.   
Similarly, we examined differences in each variable according to treatment 
strategy using Pearson Chi-squared tests and analysis of variance.  To estimate the 
effect of treatment strategy on aggregate and IA costs and days, we used a multivariable 
generalized linear model with a log link function and a gamma distribution (GLM-LG)29,30.  




distribution of outcomes approximately normal and estimated effects without bias.  For 
unplanned readmission costs and days, we used multivariable two-part models31-33.  In 
the first part of the two-part models, logistic regression was used to estimate whether 
patients had no readmission versus readmission (indicated by zero versus any costs or 
inpatient days). In the second part of the model, GLM-LG accounted for total costs and 
LOS conditional upon any positive outcome, given that majority of patients had no 
readmission31-33.  For the aggregate number of admissions and binary outcome of any 
unplanned readmission, we used a negative binomial model and a logistic model, 
respectively.  The coefficients of all estimations were converted into average marginal 
effects (AME), allowing us to interpret the effect of treatment strategy on outcomes in 
terms of outcome values (i.e., dollars, inpatient days, number of admissions, and 
probability of readmission).   We performed 2 sensitivity analyses to confirm the validity 
of our methodology. First, we defined IA that occurred (i) in January only and (ii) 
between January and March, allowing us to track total costs, inpatient days, and 
unplanned readmissions for 11 and 9 months, respectively. Second, we estimated total 
charges instead of total costs.  
All analyses were conducted with Stata MP v.16.0 and accounted for the 






CHAPTER 3:  RESULTS 
Trends in SAVR, TAVR, and MT 
In the analysis of the rates of SAVR, TAVR, and MT, the sample population 
included 366,909 patients with IA discharges for aortic valve disease and one of the 
following procedures or diagnoses:  SAVR (n = 64,695), TAVR (n = 18,107), CHF (n = 
276,955), UA (n = 11,074), NSTEMI (n = 47,749), or syncope (n = 21,858).  The average 
age was 77.8 years, and 48.7% of the study population was female.  Fifty-eight percent 
(57.9%) of patients had major or extreme loss of function due to severity of illness, and 
53.0% of patients had major or extreme likelihood of dying.  Eighty-five percent (85.2%), 
3.0%, and 9.6% of patients were covered by Medicare, Medicaid, and private insurance, 
respectively (Table 1).   
The number of patients hospitalized for aortic valve disease in the first half of 
each calendar year increased by 48.1% from 57,516 in 2012 to 85,165 in 2016.  Overall, 
from 2012 to 2016, January through June, 71,704 (19.9%), 26,173 (6.7%), and 269,032 
(73.4%) patients received SAVR, TAVR, and MT, respectively.  In 2012, 21.9%, 2.6%, 
and 75.5% of patients received each therapy, respectively, however, by 2016, the 
proportion undergoing SAVR and MT decreased to 18.5% and 69.0%, while the TAVR 
group increased to 12.5% (Table 2). 
 
Therapy Subgroup Analyses 
Subgroups stratified by patient, neighborhood, and hospital characteristics 
showed similar trends (Figures 1 and 2, P < 0.01 for all).  Of note, among the patients 
≥75 years of age, the proportion of patients undergoing TAVR increased rapidly, 
exceeding the proportion undergoing SAVR in 2016 (Figure 1C, 9.3% for SAVR and 
15.1% for TAVR).  A similar trend was observed for patients with high severity of illness 




TAVR).  Furthermore, among women (Figure 2B), patients with high predicted mortality 
(Figure 2D), and patients hospitalized in a large hospital (Figure 2F) or in a teaching 
hospital (Figure 2H), the proportions receiving SAVR and TAVR were similar by 2016.  
The same was true for patients at not-for-profit hospitals (Figure 3H), with >20 inpatient 
diagnoses (Figure 3B), or living in an urban area (Figure 3D).  
 
 
Figure 1.  Trends in surgical aortic valve replacement (SAVR), transcatheter aortic valve 
replacement (TAVR), and medical therapy (MT) from 2012 to 2016:  total sample 
population and stratified by age and severity of illness.   
 
Notes:  
(i) Severity of illness: (D) low (minor or moderate loss of function) vs. (E) high (major or extreme loss of function). 
(ii) Percentages were adjusted for Healthcare Cost and Utilization Project Nationwide Readmissions Database (HCUP-NRD) 
discharge weights to generate national estimates.  
 
 In multivariable analysis using the MNL model, estimates of TAVR versus SAVR 




SAVR increased by 4.57-fold (RRR 4.57, 95% confidence interval [CI] 4.21-4.97) when 
adjusting for patient, hospital, and neighborhood characteristics.  Patients ≥85 years of 
age (RRR 51.2, 95% CI 46.1-56.7) and those with extreme loss of function (RRR 35.7, 
95% CI 29.0-43.8) were most likely to undergo TAVR rather than SAVR.  In MNL 
multivariable analysis for TAVR versus MT, the likelihood of receiving TAVR relative to 
MT continuously increased from 2012 through 2016 (RRR 4.41 versus 2012, 95% CI 
4.08-4.77) (Table 3). 
 
 
Figure 2.  Trends in surgical aortic valve replacement (SAVR), transcatheter aortic valve 
replacement (TAVR), and medical therapy (MT) from 2012 to 2016: stratified by sex, risk 
of mortality, hospital size, and hospital teaching status.   
 
Notes:  
(i) Risk of mortality: (C) low (minor or moderate likelihood of dying) vs. (D) high (major or extreme likelihood of dying).  
(ii) Non-teaching hospital category in panel (G) includes non-teaching hospitals in urban area and any hospitals in rural area.  





Therapy Sensitivity Analyses 
 In the first sensitivity analysis, when we expanded the sample population by 
defining IA as any admission for AS or AR, regardless of other conditions (i.e., SAVR, 
TAVR, CHF, UA, NSTEMI or syncope), we captured 244,432 more patients (n = 
611,341).  Among the additional patients, 98.4% (n = 240,468) patients received MT, 
and numbers of SAVR and TAVR remained virtually unchanged.  The estimates for 
SAVR vs. TAVR in the multivariate MNL model were similar both in magnitude and 
statistical significance as compared to the main analysis (Table 4).  In the second 
sensitivity analysis, when we restricted the sample population to patients only with a 
primary diagnosis of AS or AR (n = 101,834), 19.6% of SAVR, 3.8% of TAVR, and 
92.9% of MT patients were eliminated. The MNL models in this sensitivity analysis 
remained similar to the main analysis (data not shown).  In the third sensitivity analysis, 
when we looked at a 3-month window from IA (n = 519,882, SAVR 20.1%, TAVR 6.5%, 
MT 73.4%) and a 9-month window from IA (n = 195,427, SAVR 19.3%, TAVR 6.6%, MT 
74.1%), the rates of each of the 3 therapies and the multivariate MNL model estimates 






Figure 3.  Trends in surgical aortic valve replacement (SAVR), transcatheter aortic valve 
replacement (TAVR), and medical therapy (MT) from 2012 to 2016: stratified by 
diagnosis number, hospital location, neighborhood affluence, and hospital not-for-profit 
status.   
Notes:  
(i) Percentages were adjusted for HCUP-NRD discharge weights to generate national estimates.  
(ii) Diagnosis number: (A) low (10 or fewer diagnoses) vs. (B) high (more than 20 diagnoses).  
 
Trends in Cost, Inpatient Days, and Admissions 
In the analysis of costs, inpatient days, and admissions, the study population 
included 190,563 patients with aortic valve disease, of whom 66,564 (35.6%), 21,902 
(10.8%), and 102,097 (53.6%) received SAVR, TAVR, and MT alone, respectively.  
Patient characteristics are presented in Table 5.  Notably, the average age was 76.3 
years, 45.0% were female, the average Charlson comorbidity index was 2.1 (SD 0.9), 
the average number of inpatient procedures was 2.5 (SD 1.2), 53.6% had major or 




likelihood of dying.  Medicare, Medicaid, and private insurance covered 82.0%, 3.1%, 
and 12.5% of patients, respectively.   
The aggregate average 6-month inpatient cost including all admissions was 
$40,79041,730, corresponding to $59,743 for SAVR, $64,395 for TAVR, and $23,460 
for MT.  However, following IA, the average 6-month cost of readmissions only was 
$5505 for SAVR, $7455 for TAVR, and $10,013 for MT (Figure 4; p<0.01 for all).   
Among the total study population, the mean number of inpatient days was 10.611.5 
days for all admissions across 6 months. IA was longer for SAVR (10.0 days) than for 
TAVR (7.0 day) or MT (5.3 days).  However, the average number of unplanned 
readmission inpatient days was 2.0 for SAVR, 3.0 for TAVR, and 4.3 for MT (Figure 5; 







Figure 4.  Total costs during all admissions, index admission only, and readmissions 
only (n=190,563). 
Notes:  
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).  
(ii) Lower, middle, and upper hinges of box graph represent 25th percentile, 50th percentile (median), and 75th percentile of costs. 
Lower and upper whiskers represent Tukey’s interquartile ranges34.  
(iii) •: mean, ♦: 5th percentile, ▲: 95th percentile  












(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).  
(ii) Lower, middle, and upper hinges of box graph represent 25th percentile, 50th percentile (median), and 75th percentile of days. 
Lower and upper whiskers represent Tukey’s interquartile ranges34.  
(iii) •: mean, ♦: 5th percentile, ▲: 95th percentile  
(iv) All values adjusted for HCUP-NRD discharge weights to generate nationally-representative estimates. 
 
The average number of total admissions over 6 months was 1.61.0, 
corresponding to 1.3 for SAVR, 1.5 for TAVR, and 1.7 for MT. The probability of any 
readmission followed the same trend:  0.23 for SAVR, 0.32 for TAVR, and 0.43 for MT 
(p<0.01 for all).  
 In multivariable analysis (Table 6), compared to patients receiving SAVR, total 
costs during IA were higher among patients receiving TAVR by $4246 (AME; 95% 
confidence interval [CI] $3679, $4813) but lower among patients receiving MT by 




SAVR, total costs during all unplanned readmissions were higher among patients 
receiving TAVR by $4044 (AME; 95% CI $3643, $4444) and by $4,164 among patients 
receiving MT (AME; 95% CI $3888, $4440).  
In multivariable analysis for number of inpatient days (Table 7), compared to 
patients receiving SAVR, IA was shorter by 3.2 days among patients receiving TAVR 
(AME; 95% CI -3.3, -3.1) and by 2.7 days among patients receiving MT (AME; 95% CI -
2.8, -2.6).  However, compared to patients receiving SAVR, 6-month unplanned 
readmission inpatient days were higher by 1.5 days among patients receiving TAVR 
(AME; 95% CI 1.4, 1.7) and by 1.6 days among patients receiving MT (AME; 95% CI 
1.4, 1.7).  
In multivariable analysis for number of admissions and any unplanned 
readmission (Table 8), compared to patients receiving SAVR, the probability of 
readmission was higher by 0.18 (AME; 95% CI 0.16, 0.19) among patients receiving 
TAVR and by 0.07 (AME; 95% CI 0.06, 0.07) among patients receiving MT.  
The average cost of TAVR IA was higher than SAVR IA from 2012-2016, 
however, costs of TAVR IA has decreased rapidly after 2013, and the IA cost difference 
between TAVR and SAVR was not statistically significant in 2016 ($52,487 for TAVR vs. 
$52,204 for SAVR, p=0.66; Figure 6). Inpatient days and readmission rates for TAVR 
decreased over time as well. While average IA inpatient days for TAVR (9.2 days) and 
SAVR (10.3 days) were similar in 2013, by 2016, IA was much shorter for TAVR (5.4 










(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).  
(ii) Sum (both IA and RA), IA (index admission), RA (readmissions).  
(ii) Mean was adjusted for HCUP-NRD discharge weights to generate nationally representative estimates. 
 
Cost Subgroup Analyses 
Most results were similar in subgroup analyses. However, during IA only, in 
comparison to the total study population, the excess cost for TAVR vs. SAVR was less 
among patients age ≤74 (AME $1334; 95% CI $609, $2528), small and medium size 
hospitals (AME $3755; 95% CI $2548, $4942), non-teaching hospitals and hospitals in 
non-metropolitan areas (AME $2940; 95% CI $1674, $4206), and poor neighborhoods 
(AME $3673; 95% CI $2877, $4470).  Conversely, the excess cost of TAVR vs. SAVR IA 
was most pronounced (AME $13,485; 95% CI $12,427, $14,543) among patients with 




For inpatient days, TAVR resulted in shorter IA than SAVR (AME -3.2 days, 95% 
CI, -3.3, -3.1) among the total study population, however this effect was less dramatic 
among patients with minor or moderate loss of function (AME -0.7, 95% CI -0.9, -0.4). 
During readmissions, TAVR was actually associated with more inpatient days than 
SAVR (AME 1.5, 95% CI, 1.4, 1.7) among the total study population, but only a very 
modest effect was observed in patients with extreme loss of function (AME 0.2, 95% CI, 
0.2, 0.2).   
 
Cost Sensitivity Analyses 
In the first sensitivity analyses, when we defined IA during January only with 11 
months of follow-up or during January through March with 9 months of follow-up, most 
results were similar to the primary analysis (Table 9).  In the second sensitivity analysis, 
the average aggregate total charge was $155,949±177,656 (Figure 7). Analyses for total 










(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).  
(ii) Lower, middle, and upper hinges of box graph represent 25th percentile, 50th percentile (median), and 75th percentile of charges. 
Lower and upper whiskers represent Tukey’s interquartile ranges34.  
(iii) •: mean, ♦: 5th percentile, ▲: 95th percentile  





Table 1.  Patient characteristics and neighborhood information among total sample 
population and stratified by treatment strategy (No. (%)). 
  Total sample  SAVR  TAVR  MT  p-value  
  (n = 366909) (n = 71704) (n = 26173) (n = 269032)   
Age category          p < 0.01 
    64 or less  47077 (13.2) 20399 (43.9) 1062 (2.1) 25616 (54.0) - 
    65-74  71762 (19.6) 24171 (33.9) 3813 (5.0) 43778 (61.1) - 
    75-84 117206 (32.0) 22780 (19.7) 10333 (8.3) 84093 (72.0) - 
    85 or above  130864 (35.2) 4354 (3.4) 10965 (8.0) 115545 (88.6) - 
Women  177681 (48.7) 24405 (14.1) 12145 (6.4) 141131 (79.5) p < 0.01 
Severity of illness          p < 0.01 
    Minor loss of function  17761 (4.9) 4918 (27.9) 152 (0.8) 12691 (71.3) - 
    Moderate loss of function  134278 (37.2) 32093 (24.0) 3775 (2.7) 98410 (73.3) - 
    Major loss of function  164340 (44.5) 27935 (17.3) 10948 (6.4) 125457 (76.3) - 
    Extreme loss of function  50530 (13.4) 6758 (14.1) 11298 (21.5) 32474 (64.4) - 
Risk of mortality          p < 0.01 
    Minor likelihood of dying 21914 (6.1) 11029 (51.0) 1363 (5.6) 9522 (43.4) - 
    Moderate likelihood of dying 148353 (40.8) 32363 (22.1) 12622 (7.9) 103368 (70.0) - 
    Major likelihood of dying 152437 (41.3) 21673 (14.4) 10519 (6.6) 120245 (79.0) - 
    Extreme likelihood of dying 44205 (11.8) 6639 (15.8) 1669 (3.6) 35897 (80.6) - 
Number of diagnoses          p < 0.01 
    1-10  48545 (13.8) 18923 (39.4) 3011 (5.5) 26611 (55.1) - 
    11-15 111841 (30.6) 24060 (21.3) 8277 (6.8) 79504 (71.9) - 
    16-20  115774 (31.3) 16990 (14.9) 9137 (7.5) 89647 (77.6) - 
    21-35  90749 (24.3) 11731 (13.6) 5748 (6.4) 73270 (80.1) - 
Insurance status          p < 0.01 
   Medicare  311844 (85.2) 49467 (16.1) 24362 (7.4) 238013 (76.5) - 
   Medicaid  11843 (3.0) 3319 (28.6) 244 (2.0) 8280 (69.4) - 
   Private  35300 (9.6) 16735 (48.8) 1221 (3.2) 17346 (48.0) - 
   Self-pay  2733 (0.8) 824 (30.9) 87 (2.7) 1822 (66.4) - 
   No charge/other  5188 (1.4) 1359 (27.4) 259 (5.4) 3570 (67.3) - 
Neighborhood median household income        p < 0.01 
    Bottom quartile  86423 (24.9) 15393 (17.9) 5117 (5.6) 65910 (76.5) - 
    Second quartile  91441 (26.1) 18112 (20.3) 6224 (6.6) 67106 (73.1) - 
    Third quartile  94957 (25.5) 19187 (20.8) 7075 (7.2) 68697 (72.0) - 
    Top quartile  94087 (23.5) 19012 (20.6) 7757 (7.6) 67319 (71.8) - 
Patient urban-rural classification        p < 0.01 
    Counties < 249,999 88376 (28.6) 18706 (21.2) 5962 (6.5) 63709 (72.3) - 
    Counties 250,000-999,999  78109 (20.6) 16786 (22.0) 5625 (7.0) 55698 (71.0) - 
    Fringe counties, ≥1 million 97908 (27.4) 18372 (19.2) 7697 (7.1) 71839 (73.7) - 
    Central counties, ≥1 million 102516 (23.4) 17841 (17.4) 6889 (6.4) 77786 (76.2) - 
Notes: 
(i) Percentages adjusted for HCUP-NRD discharge weights to generate national estimates, accounting for slight deviation from the 
percentage calculated from the raw numbers. 






Table 2.  Treatment strategy, year, and hospital characteristics among total sample 
population and stratified by treatment strategy (No. (%)). 
  Total sample  SAVR  TAVR  MT  p-value  
  (n = 366909) (n = 71704) (n = 26173) (n = 269032)   
Treatment strategy          p < 0.01 
    SAVR  71704 (19.9) 71704 (100) 0 (0.0) 0 (0.0) - 
    TAVR  26173 (6.7) 0 (0) 26173 (100) 0 (0.0) - 
    MT 269032 (73.4) 0 (0) 0 (0) 269032 (100) - 
            
Year          p < 0.01 
    2012 57516 (18.2) 12290 (21.9) 1557 (2.6) 43669 (75.5) - 
    2013 65880 (19.4) 13608 (20.7) 3040 (4.5) 49232 (74.8) - 
    2014 69121 (19.7) 14012 (20.5) 4045 (5.6) 51064 (73.9) - 
    2015 89227 (21.8) 16247 (18.4) 6904 (7.6) 66076 (74.0) - 
    2016 85165 (20.9) 15547 (18.5) 10627 (12.5) 58991 (69.0) - 
Hospital ownership          p < 0.01 
    Private, investor-owned  43434 (10.7) 7806 (17.9) 1349 (2.9) 34279 (79.2) - 
    Private, not-for-profit  283908 (79.2) 57237 (20.6) 21957 (7.2) 204714 (72.2) - 
    Government, non-federal  39567 (10.1) 6661 (16.8) 2867 (6.9) 30039 (76.3) - 
Hospital size          p < 0.01 
    Small  36119 (11.0) 3892 (11.4) 768 (1.9) 31459 (86.7) - 
    Medium  89810 (23.1) 14101 (16.1) 4004 (4.1) 71705 (79.8) - 
    Large  240980 (65.9) 53711 (22.7) 21401 (8.5) 165868 (68.8) - 
Hospital teaching status          p < 0.01 
    Urban, non-teaching  109350 (27.6) 15686 (14.9) 2208 (2.0) 91456 (83.1) - 
    Rural 22285 (8.3) 1215 (5.7) 237 (1.0) 20833 (93.3) - 
    Urban, teaching  235274 (64.1) 54803 (24.0) 23728 (9.5) 156743 (66.5) - 
Notes: 
(i) Percentages adjusted for HCUP-NRD discharge weights to generate national estimates, accounting for slight deviation from the 
percentage calculated from the raw numbers. 







Table 3.  Association of year, patient characteristics, and hospital characteristics with 
treatment strategy (n = 366,909). 
  TAVR vs. SAVR  SAVR vs. MT  TAVR vs. MT  
  RRR (95% CI)  RRR (95% CI)  RRR (95% CI)  
Year        
    2012 1 [reference] 1 [reference] 1 [reference] 
    2013 1.79 (1.64-1.96) 1.00 (0.96-1.04) 1.78 (1.64-1.94) 
    2014 2.13 (1.95-2.33) 0.96 (0.92-0.99) 2.04 (1.87-2.21) 
    2015 2.84 (2.61-3.09) 0.90 (0.87-0.94) 2.56 (2.37-2.77) 
    2016 4.57 (4.21-4.97) 0.96 (0.93-1.00) 4.41 (4.08-4.77) 
Age category        
    64 or less  1 [reference] 1 [reference] 1 [reference] 
    65-74  2.64 (2.39-2.92) 1.07 (1.03-1.11) 2.84 (2.57-3.13) 
    75-84 8.51 (7.72-9.37) 0.62 (0.59-0.64) 5.25 (4.77-5.77) 
    85 or above  51.2 (46.1-56.7) 0.09 (0.09-0.10) 4.81 (4.37-5.30) 
Women  1.29 (1.24-1.34) 0.62 (0.61-0.63) 0.80 (0.77-0.83) 
Severity of illness        
    Minor loss of function  1 [reference] 1 [reference] 1 [reference] 
    Moderate loss of function  3.16 (2.61-3.84) 1.89 (1.79-1.99) 5.97 (4.94-7.23) 
    Major loss of function  17.8 (14.6-21.7) 2.25 (2.12-2.39) 40.2 (33.3-48.8) 
    Extreme loss of function  35.7 (29.0-43.8) 2.58 (2.38-2.79) 92.0 (75.3-112) 
Risk of mortality        
    Minor likelihood of dying 1 [reference] 1 [reference] 1 [reference] 
    Moderate likelihood of dying 0.55 (0.51-0.60) 0.56 (0.53-0.58) 0.31 (0.28-0.33) 
    Major likelihood of dying 0.16 (0.14-0.17) 0.41 (0.39-0.43) 0.06 (0.06-0.07) 
    Extreme likelihood of dying 0.01 (0.01-0.01) 0.44 (0.41-0.48) <0.01 (0.00-0.00) 
Number of diagnoses        
    1-10  1 [reference] 1 [reference] 1 [reference] 
    11-15 1.47 (1.38-1.57) 0.44 (0.43-0.46) 0.65 (0.61-0.69) 
    16-20  1.95 (1.82-2.08) 0.27 (0.26-0.28) 0.53 (0.49-0.56) 
    21-35  1.58 (1.46-1.70) 0.22 (0.21-0.23) 0.34 (0.32-0.37) 
Insurance status        
   Medicare  1 [reference] 1 [reference] 1 [reference] 
   Medicaid  0.57 (0.47-0.68) 0.86 (0.81-0.91) 0.49 (0.41-0.58) 
   Private  0.48 (0.44-0.53) 1.87 (1.80-1.94) 0.91 (0.83-0.99) 
   Self-pay  0.65 (0.50-0.85) 0.87 (0.78-0.97) 0.56 (0.44-0.73) 
   No charge/other  0.72 (0.60-0.85) 1.02 (0.94-1.12) 0.73 (0.62-0.87) 
Neighborhood median household income      
    Bottom quartile  1 [reference] 1 [reference] 1 [reference] 
    Second quartile  0.94 (0.89-1.00) 1.34 (1.30-1.38) 1.26 (1.19-1.33) 
    Third quartile  0.93 (0.88-0.99) 1.43 (1.38-1.47) 1.32 (1.26-1.40) 
    Top quartile  0.90 (0.84-0.95) 1.61 (1.56-1.67) 1.44 (1.37-1.53) 
Patient urban-rural classification        
    Counties <249,999 1 [reference] 1 [reference] 1 [reference] 
    Counties 250,000-999,999  0.93 (0.88-0.99) 0.72 (0.69-0.74) 0.67 (0.63-0.71) 
    Fringe counties, ≥1 million 1.09 (1.02-1.16) 0.63 (0.61-0.65) 0.68 (0.65-0.72) 
    Central counties, ≥1 million 0.93 (0.88-0.99) 0.51 (0.50-0.53) 0.48 (0.45-0.51) 
Hospital ownership        
    Private, investor-owned  1 [reference] 1 [reference] 1 [reference] 
    Private, not-for-profit  1.33 (1.24-1.43) 0.87 (0.83-0.90) 1.15 (1.08-1.23) 
     Government, non-federal 1.77 (1.61-1.94) 0.54 (0.52-0.57) 0.96 (0.88-1.04) 
Hospital size        
    Small  1 [reference] 1 [reference] 1 [reference] 
    Medium  1.62 (1.45-1.80) 1.57 (1.49-1.65) 2.54 (2.30-2.79) 




Hospital teaching status        
    Urban, non-teaching  1 [reference] 1 [reference] 1 [reference] 
    Rural  1.34 (1.13-1.57) 0.28 (0.26-0.30) 0.37 (0.32-0.43) 





Table 4.  Sensitivity analysis:  association of year, patient characteristics, and hospital 
characteristics with treatment strategy in patients admitted with any diagnosis of AS or 
AR (n = 611,341). 
  TAVR vs. SAVR  SAVR vs. MT  TAVR vs. MT  
  RRR (95% CI)  RRR (95% CI)  RRR (95% CI)  
Year        
    2012 1 [reference] 1 [reference] 1 [reference] 
    2013 1.77 (1.63-1.93) 0.97 (0.94-1.01) 1.72 (1.59-1.86) 
    2014 2.13 (1.97-2.32) 0.94 (0.91-0.97) 2.00 (1.86-2.17) 
    2015 2.86 (2.65-3.10) 0.87 (0.84-0.90) 2.49 (2.31-2.68) 
    2016 4.85 (4.49-5.24) 0.81 (0.78-0.84) 3.94 (3.66-4.23) 
Age category        
    64 or less  1 [reference] 1 [reference] 1 [reference] 
    65-74  2.85 (2.59-3.14) 1.04 (1.01-1.08) 2.98 (2.71-3.27) 
    75-84 9.53 (8.69-10.4) 0.63 (0.61-0.65) 5.98 (5.46-6.54) 
    85 or above  55.2 (49.9-60.9) 0.11 (0.11-0.12) 6.15 (5.61-6.74) 
Women  1.31 (1.26-1.36) 0.60 (0.58-0.61) 0.78 (0.76-0.81) 
Severity of illness        
    Minor loss of function  1 [reference] 1 [reference] 1 [reference] 
    Moderate loss of function  3.82 (3.24-4.50) 2.07 (1.99-2.15) 7.90 (6.72-9.29) 
    Major loss of function  21.6 (18.2-25.5) 2.38 (2.27-2.49) 51.3 (43.5-60.5) 
    Extreme loss of function  40.8 (34.1-48.9) 2.58 (2.41-2.76) 105 (89-125) 
Risk of mortality        
    Minor likelihood of dying 1 [reference] 1 [reference] 1 [reference] 
    Moderate likelihood of dying 0.48 (0.45-0.52) 1.24 (1.20-1.28) 0.60 (0.56-0.64) 
    Major likelihood of dying 0.13 (0.12-0.14) 1.12 (1.07-1.16) 0.14 (0.13-0.15) 
    Extreme likelihood of dying 0.01 (0.01-0.01) 1.27 (1.19-1.36) 0.01 (0.01-0.01) 
Number of diagnoses        
    1-10  1 [reference] 1 [reference] 1 [reference] 
    11-15 1.35 (1.28-1.43) 0.61 (0.59-0.63) 0.82 (0.78-0.87) 
    16-20  1.64 (1.55-1.75) 0.42 (0.41-0.44) 0.70 (0.66-0.74) 
    21-35  1.26 (1.17-1.35) 0.36 (0.35-0.37) 0.45 (0.42-0.48) 
Insurance status        
   Medicare  1 [reference] 1 [reference] 1 [reference] 
   Medicaid  0.51 (0.43-0.61) 0.87 (0.83-0.92) 0.45 (0.38-0.53) 
   Private  0.46 (0.43-0.50) 1.67 (1.62-1.72) 0.78 (0.72-0.84) 
   Self-pay  0.57 (0.44-0.74) 0.94 (0.86-1.03) 0.54 (0.42-0.70) 
   No charge/other  0.70 (0.59-0.83) 1.01 (0.94-1.09) 0.71 (0.61-0.83) 
Neighborhood median household income      
    Bottom quartile  1 [reference] 1 [reference] 1 [reference] 
    Second quartile  0.97 (0.92-1.02) 1.24 (1.21-1.28) 1.20 (1.14-1.26) 
    Third quartile  0.96 (0.91-1.01) 1.29 (1.25-1.33) 1.23 (1.17-1.29) 
    Top quartile  0.96 (0.90-1.01) 1.37 (1.33-1.42) 1.31 (1.25-1.38) 
Patient urban-rural classification      
    Counties <249,999 1 [reference] 1 [reference] 1 [reference] 
    Counties 250,000-999,999  0.92 (0.87-0.97) 0.71 (0.69-0.73) 0.65 (0.62-0.68) 
    Fringe counties, ≥1 million 1.11 (1.05-1.17) 0.64 (0.62-0.66) 0.70 (0.67-0.74) 
    Central counties, ≥1 million 0.92 (0.87-0.97) 0.52 (0.51-0.54) 0.48 (0.46-0.51) 
Hospital ownership        
    Private, investor-owned  1 [reference] 1 [reference] 1 [reference] 
    Private, not-for-profit  1.38 (1.29-1.48) 0.85 (0.82-0.87) 1.17 (1.09-1.24) 
    Government, non-federal 1.76 (1.61-1.91) 0.56 (0.54-0.59) 0.99 (0.91-1.07) 




    Small  1 [reference] 1 [reference] 1 [reference] 
    Medium  1.65 (1.49-1.83) 1.62 (1.54-1.69) 2.67 (2.43-2.93) 
    Large  2.74 (2.49-3.01) 2.89 (2.77-3.02) 7.91 (7.25-8.63) 
Hospital teaching status        
    Urban, non-teaching  1 [reference] 1 [reference] 1 [reference] 
    Rural  1.32 (1.13-1.54) 0.30 (0.28-0.32) 0.39 (0.34-0.45) 





Table 5.  Patient, hospital, and neighborhood characteristics among total study 
population and stratified by treatment strategy (No. (%)).   
  Total study SAVR  TAVR  MT  P-value  
 population          
  (n = 190,563) (n = 66,564;  (n = 21,902;  (n = 102,097;   
               35.6%)             10.8%)             53.6%)   
Age category            < 0.01 
    64 29320 (15.8) 19084 (29.2) 863 (4.0) 9373 (9.3) - 
    65-74  41428 (21.7) 22585 (33.5) 3157 (14.3) 15686 (15.3) - 
    75-84 60847 (31.9) 21024 (31.5) 8669 (39.7) 31154 (30.5) - 
    85 58968 (30.6) 3871 (5.8) 9213 (41.9) 45884 (44.8) - 
Women  85231 (45.0) 22444 (34.1) 10042 (46.0) 52745 (52.0)   < 0.01 
Charlson comorbidity index            < 0.01 
    0-1 59104 (31.4) 35263 (53.4) 5452 (24.9) 18389 (18.2) - 
    2-3 74157 (39.0) 22386 (33.6) 9296 (42.5) 42475 (41.9) - 
    4-5 43635 (22.7) 7234 (10.7) 5500 (25.1) 30901 (30.2) - 
    6 13667 (6.9) 1681 (2.4) 1654 (7.5) 10332 (9.7) - 
Number of inpatient procedures            < 0.01 
    0  48881 (25.6) 0 (0) 0 (0.0) 48881 (48.9)   
    1-2 49863 (26.2) 10402 (15.8) 8743 (39.4) 30718 (29.7)   
    3-4 38493 (20.2) 19959 (30.0) 6293 (29.0) 12241 (11.6)   
    5 53326 (28.0) 36203 (54.2) 6866 (31.5) 10257 (9.8)   
Severity of illness            < 0.01 
    Minor loss of function  11720 (6.2) 4295 (6.5) 109 (0.5) 7316 (7.2) - 
    Moderate loss of function  75541 (40.2) 29646 (44.6) 2024 (9.4) 43871 (43.4) - 
    Major loss of function  78008 (40.8) 26749 (39.9) 6630 (30.5) 44629 (43.4) - 
    Extreme loss of function  25294 (12.8) 5874 (8.9) 13139 (59.6) 6281 (6.0) - 
Risk of mortality            < 0.01 
    Minor likelihood of dying 16450 (8.8) 10225 (15.6) 1220 (5.5) 5005 (5.0) - 
    Moderate likelihood of dying 82482 (43.5) 30019 (45.2) 10001 (45.5) 42462 (42.0) - 
    Major likelihood of dying 75857 (39.4) 20619 (30.5) 9166 (42.1) 46072 (44.8) - 
    Extreme likelihood of dying 15774 (8.3) 5701 (8.7) 1515 (6.9) 8558 (8.3) - 
Insurance status            < 0.01 
    Medicare  156247 (82.0) 45571 (68.4) 20274 (92.5) 90400 (88.9) - 
    Medicaid  6349 (3.1) 2974 (4.2) 202 (0.9) 3173 (2.9) - 
    Private  23535 (12.5) 15963 (24.2) 1080 (4.9) 6494 (6.2) - 
    Self-pay  1602 (0.9) 755 (1.2) 95 (0.4) 753 (0.7) - 
    No charge/other  2829 (1.5) 1301 (2.0) 251 (1.3) 1277 (1.2) - 
Neighborhood median household income          < 0.01 
    Bottom quartile  43864 (24.2) 14080 (22.0) 4213 (20.5) 25568 (26.3) - 
    Second quartile  47721 (26.2) 16770 (26.6) 5212 (25.5) 25739 (26.2) - 
    Third quartile  49682 (25.8) 17828 (26.7) 5889 (27.0) 25967 (24.9) - 
    Top quartile  49296 (23.8) 17886 (24.7) 6588 (27.0) 24824 (22.6) - 
Patient urban-rural classification          < 0.01 
    Counties <249,999 46872 (29.0) 17346 (30.4) 5012 (27.5) 24514 (28.4) - 
    Counties 250,000-999,999  41545 (21.2) 15607 (22.8) 4707 (21.4) 21231 (20.0) - 
    Fringe counties, ≥1 million 51267 (27.5) 17135 (26.5) 6442 (29.1) 27690 (27.8) - 
    Central counties, ≥1 million 50879 (22.3) 16476 (20.3) 5741 (22.0) 28662 (23.7) - 
Hospital ownership            < 0.01 
    Private, investor-owned  22298 (10.6) 7398 (9.9) 1191 (5.0) 13709 (12.2) - 




    Government, non-federal  19771 (9.6) 5888 (8.1) 2202 (9.3) 11681 (10.7) - 
Hospital size            < 0.01 
    Small  16690 (9.8) 3802 (6.6) 725 (3.5) 12163 (13.3) - 
    Medium  44326 (22.0) 13304 (19.0) 3528 (14.9) 27494 (25.4) - 
    Large  129547 (68.2) 49458 (74.4) 17649 (81.7) 62440 (61.3) - 
Hospital teaching status           < 0.01 
    Urban, non-teaching  51878 (25.5) 14822 (21.0) 1951 (8.6) 35105 (31.9) - 
    Non-metropolitan 9409 (6.8) 1044 (2.2) 178 (1.1) 8187 (10.9) - 
    Urban, teaching  129276 (67.7) 50698 (76.8) 19773 (90.2) 58805 (57.2) - 
Year            < 0.01 
    2012 29235 (17.9) 11323 (19.8) 1239 (6.8) 16673 (18.8) - 
    2013 33685 (19.2) 12551 (20.1) 2466 (12.8) 18668 (19.9) - 
    2014 35400 (19.4) 13012 (20.2) 3177 (15.3) 19211 (19.7) - 
    2015 44847 (21.1) 15114 (20.2) 5730 (24.5) 24003 (21.0) - 
    2016 47396 (22.4) 14564 (19.7) 9290 (40.6) 23542 (20.6) - 
Notes:  
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).   
(ii) Percentages were adjusted for HCUP-NRD discharge weights to generate national estimates, which accounts for their slight 
deviation from the percentage calculated from the raw numbers. 





Table 6.  Association of treatment strategy with total cost:  total cost during all 
admissions, index admission only, and readmissions only (n = 190,563).   
  All admissions  Index admission only  Readmissions only  
  AME in $ (95% CI)  AME in $ (95% CI)  AME in $ (95% CI)  
Treatment strategy        
    SAVR  - - - 
    TAVR  6559 (5750, 7369) 4246 (3679, 4813) 4044 (3643, 4444) 
    MT  -22825 (-23360, -22291) -25556 (-25886, -25226) 4164 (3888, 4440) 
Age category        
    64 - - - 
    65-74  -6058 (-6929, -5187) -1642 (-2171, -1114) -3359 (-3905, -2812) 
    75-84 -8192 (-9077, -7307) -2660 (-3196, -2125) -4023 (-4562, -3483) 
    85 -11934 (-12854, -11015) -4440 (-5008, -3873) -5113 (-5655, -4571) 
Women  305 (-52, 662) -80 (-305, 144) 274 (88, 460) 
Charlson comorbidity index        
    0-1 - - - 
    2-3 5435 (4986, 5885) 1670 (1381, 1959) 2829 (2609, 3049) 
    4-5 9316 (8740, 9892) 3688 (3330, 4046) 4327 (4046, 4609) 
    6 9774 (8928, 10619) 6608 (6073, 7142) 3926 (3519, 4334) 
Number of inpatient procedures        
    0 - - - 
    1-2 16398 (16015, 16780) 9008 (8800, 9217) 5271 (5056, 5487) 
    3-4 22607 (22129, 23085) 16623 (16384, 16863) 4838 (4537, 5140) 
    5 30738 (30180, 31295) 30058 (29720, 30397) 2697 (2333, 3061) 
Severity of illness        
    Minor loss of function  - - - 
    Moderate loss of function  5784 (5116, 6452) 1114 (619, 1609) 2672 (2296, 3048) 
    Major loss of function  9645 (8891, 10400) 5006 (4449, 5564) 3382 (2965, 3800) 
    Extreme loss of function  8018 (7025, 9011) 10404 (9596, 11212) -3632 (-4080, -3185) 
Risk of mortality        
    Minor likelihood of dying - - - 
    Moderate likelihood of dying 5264 (4733, 5796) 823 (466, 1181) 3098 (2786, 3410) 
    Major likelihood of dying 7451 (6770, 8132) 3599 (3145, 4054) 3206 (2830, 3581) 
    Extreme likelihood of dying 11519 (10334, 12704) 11147 (10269, 12025) -185 (-709, 340) 
Insurance status        
    Medicare  - - - 
    Medicaid  4143 (2723, 5563) 2999 (2139, 3860) 942 (221, 1663) 
    Private  -6078 (-6697, -5458) -521 (-968, -73) -3629 (-3928, -3330) 
    Self-pay  -9276 (-11205, -7346) -934 (-2812, 945) -5246 (-5855, -4638) 
    No charge/other  -6225 (-7638, -4812) 1114 (-151, 2379) -4852 (-5355, -4349) 
Neighborhood median household income      
    Bottom quartile  - - - 
    Second quartile  963 (472, 1454) 1253 (948, 1557) 100 (-158, 359) 
    Third quartile  2015 (1490, 2540) 2719 (2394, 3044) 74 (-192, 339) 
    Top quartile  4548 (3990, 5107) 5162 (4810, 5514) 495 (202, 788) 
Patient urban-rural classification      
    Counties <249,999 - - - 
    Counties 250,000-999,999  -386 (-896, 124) -1013 (-1351, -674) 403 (151, 654) 
    Fringe counties, ≥1 million 2524 (1938, 3110) -298 (-663, 68) 2010 (1721, 2300) 




Hospital ownership        
    Private, investor-owned  - - - 
    Private, not-for-profit  5526 (5048, 6005) 4179 (3886, 4471) 1488 (1238, 1739) 
    Government, non-federal  12819 (11976, 13662) 6916 (6452, 7379) 4489 (4059, 4919) 
Hospital size        
    Small  - - - 
    Medium  1090 (411, 1769) -1367 (-1825, -909) 1120 (826, 1414) 
    Large  5410 (4786, 6033) -327 (-754, 99) 3324 (3045, 3603) 
Hospital teaching status       
    Urban, non-teaching  - - - 
    Non-metropolitan -69 (-903, 765) 658 (84, 1231) 358 (-19, 736) 
    Urban, teaching  3302 (2896, 3707) 8 (-249, 265) 2008 (1805, 2211) 
Year        
    2012 - - - 
    2013 -1233 (-1904, -563) -403 (-810, 4) -779 (-1129, -429) 
    2014 -2953 (-3584, -2321) -1620 (-2001, -1239) -1182 (-1531, -833) 
    2015 -3666 (-4277, -3056) -1867 (-2244, -1491) -1458 (-1794, -1123) 
    2016 -4029 (-4638, -3420) -1549 (-1929, -1168) -1804 (-2139, -1470) 
Notes:  
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).  
(ii) Average marginal effects (AME; $) and 95% confidence interval (CI) were adjusted for HCUP-NRD discharge weights to 




Table 7.  Association of treatment strategy with inpatient days:  inpatient days during all 
admissions, index admission only, and readmissions only (n = 190,563).   
  All admissions  Index admission only  Readmissions only 
  AME in days (95% CI)  AME in days (95% CI)  AME in days (95% CI)  
Treatment strategy        
    SAVR  - - - 
    TAVR  -2.6 (-2.8, -2.4) -3.2 (-3.3, -3.1) 1.5 (1.4, 1.7) 
    MT  -1.7 (-1.8, -1.5) -2.7 (-2.8, -2.6) 1.6 (1.4, 1.7) 
Age category        
    64 - - - 
    65-74  -1.8 (-2.1, -1.6) -0.5 (-0.6, -0.4) -1.2 (-1.4, -1.0) 
    75-84 -1.6 (-1.9, -1.4) -0.2 (-0.3, -0.1) -1.2 (-1.5, -1.0) 
    85 -1.9 (-2.1, -1.6) 0.1 (-0.1, 0.2) -1.6 (-1.8, -1.4) 
Women  0.8 (0.7, 0.9) 0.5 (0.5, 0.6) 0.3 (0.2, 0.3) 
Charlson comorbidity index        
    0-1 - - - 
    2-3 2.1 (2.0, 2.3) 0.8 (0.7, 0.9) 1.2 (1.1, 1.3) 
    4-5 3.5 (3.3, 3.6) 1.6 (1.5, 1.7) 1.8 (1.7, 1.9) 
    6 3.5 (3.3, 3.8) 2.3 (2.1, 2.4) 1.5 (1.4, 1.7) 
Number of inpatient procedures        
    0 - - - 
    1-2 3.1 (3.0, 3.3) 1.1 (1.0, 1.1) 1.9 (1.8, 1.9) 
    3-4 3.2 (3.1, 3.4) 1.9 (1.9, 2.0) 1.2 (1.0, 1.3) 
    5 4.6 (4.4, 4.8) 5.1 (5.0, 5.2) 0.0 (-0.2, 0.1) 
Severity of illness        
    Minor loss of function  - - - 
    Moderate loss of function  2.3 (2.1, 2.5) 0.8 (0.7, 0.9) 1.3 (1.2, 1.5) 
    Major loss of function  3.3 (3.1, 3.6) 1.8 (1.7, 1.9) 1.6 (1.5, 1.8) 
    Extreme loss of function  0.7 (0.4, 1.0) 2.0 (1.8, 2.2) -1.3 (-1.4, -1.1) 
Risk of mortality        
    Minor likelihood of dying - - - 
    Moderate likelihood of dying 2.3 (2.2, 2.5) 0.8 (0.7, 0.9) 1.3 (1.2, 1.4) 
    Major likelihood of dying 3.7 (3.5, 3.9) 2.0 (1.9, 2.1) 1.3 (1.1, 1.4) 
    Extreme likelihood of dying 6.9 (6.5, 7.3) 4.7 (4.5, 4.9) -0.2 (-0.4, 0.0) 
Insurance status        
    Medicare  - - - 
    Medicaid  1.6 (1.2, 2.1) 1.1 (0.9, 1.3) 0.3 (0.1, 0.6) 
    Private  -2.4 (-2.6, -2.2) -0.6 (-0.7, -0.5) -1.6 (-1.7, -1.5) 
    Self-pay  -1.7 (-2.3, -1.1) 0.4 (0.0, 0.8) -2.0 (-2.3, -1.7) 
    No charge/other  -1.8 (-2.2, -1.4) 0.2 (-0.1, 0.5) -1.9 (-2.1, -1.6) 
Neighborhood median household income      
    Bottom quartile  - - - 
    Second quartile  -0.5 (-0.6, -0.3) -0.2 (-0.3, -0.1) -0.2 (-0.3, -0.1) 
    Third quartile  -0.9 (-1.1, -0.8) -0.3 (-0.4, -0.3) -0.5 (-0.6, -0.4) 
    Top quartile  -1.0 (-1.2, -0.9) -0.3 (-0.4, -0.2) -0.6 (-0.7, -0.5) 
Patient urban-rural classification      
    Counties <249,999 - - - 
    Counties 250,000-999,999  0.3 (0.2, 0.5) 0.0 (-0.1, 0.1) 0.3 (0.2, 0.4) 
    Fringe counties, ≥1 million 1.6 (1.5, 1.8) 0.5 (0.4, 0.6) 1.0 (0.9, 1.1) 




Hospital ownership        
    Private, investor-owned  - - - 
    Private, not-for-profit  -0.3 (-0.5, -0.2) -0.3 (-0.4, -0.3) 0.1 (-0.1, 0.2) 
    Government, non-federal  1.5 (1.3, 1.8) 0.3 (0.2, 0.4) 1.0 (0.9, 1.2) 
Hospital size        
    Small  - - - 
    Medium  0.9 (0.7, 1.1) 0.2 (0.1, 0.3) 0.6 (0.5, 0.7) 
    Large  2.4 (2.2, 2.6) 0.6 (0.5, 0.7) 1.5 (1.4, 1.6) 
Hospital teaching status       
    Urban, non-teaching  - - - 
    Non-metropolitan 0.1 (-0.1, 0.4) 0.2 (0.0, 0.3) 0.0 (-0.1, 0.2) 
    Urban, teaching  1.4 (1.3, 1.5) 0.3 (0.3, 0.4) 0.9 (0.8, 1.0) 
Year        
    2012 - - - 
    2013 -0.4 (-0.6, -0.2) -0.1 (-0.2, 0.0) -0.3 (-0.5, -0.2) 
    2014 -0.7 (-0.9, -0.5) -0.2 (-0.3, -0.1) -0.4 (-0.6, -0.3) 
    2015 -1.1 (-1.3, -0.9) -0.4 (-0.5, -0.3) -0.5 (-0.7, -0.4) 
    2016 -1.7 (-1.9, -1.5) -0.8 (-0.9, -0.7) -0.7 (-0.9, -0.6) 
Notes:  
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).  
(ii) Average marginal effects (AME; days) and 95% confidence interval (CI) were adjusted for HCUP-NRD discharge weights to 




Table 8.  Association of treatment strategy with aggregate number of admissions and 
probability of any unplanned readmission (n = 190,563).   
  All admissions  Any readmission 
  AME in No. (95% CI)  AME in Prob. (95% CI)  
Treatment strategy      
    SAVR  - - 
    TAVR  0.3 (0.2, 0.3) 0.18 (0.16, 0.19) 
    MT  0.2 (0.2, 0.2) 0.07 (0.06, 0.07) 
Age category      
    64 - - 
    65-74  -0.2 (-0.2, -0.1) -0.06 (-0.07, -0.05) 
    75-84 -0.2 (-0.2, -0.2) -0.04 (-0.05, -0.03) 
    85 -0.2 (-0.3, -0.2) -0.04 (-0.05, -0.03) 
Women  0.0 (0.0, 0.0) 0.01 (0.01, 0.02) 
Charlson comorbidity index      
    0-1 - - 
    2-3 0.2 (0.2, 0.2) 0.09 (0.08, 0.09) 
    4-5 0.3 (0.3, 0.3) 0.13 (0.12, 0.14) 
    6 0.3 (0.2, 0.3) 0.13 (0.12, 0.14) 
Number of inpatient procedures      
    0 - - 
    1-2 0.2 (0.2, 0.2) 0.12 (0.11, 0.12) 
    3-4 0.0 (-0.1, 0.0) 0.01 (0.00, 0.02) 
    5 -0.3 (-0.3, -0.3) -0.16 (-0.16, -0.15) 
Severity of illness      
    Minor loss of function  - - 
    Moderate loss of function  0.2 (0.2, 0.2) 0.05 (0.04, 0.07) 
    Major loss of function  0.1 (0.1, 0.1) 0.02 (0.01, 0.03) 
    Extreme loss of function  -0.4 (-0.4, -0.4) -0.28 (-0.29, -0.27) 
Risk of mortality      
    Minor likelihood of dying - - 
    Moderate likelihood of dying 0.2 (0.1, 0.2) 0.07 (0.06, 0.08) 
    Major likelihood of dying 0.1 (0.1, 0.1) 0.04 (0.03, 0.05) 
    Extreme likelihood of dying 0.0 (-0.1, 0.0) -0.05 (-0.06, -0.03) 
Insurance status      
    Medicare  - - 
    Medicaid  0.0 (0.0, 0.1) -0.01 (-0.02, 0.01) 
    Private  -0.3 (-0.3, -0.3) -0.12 (-0.13, -0.11) 
    Self-pay  -0.3 (-0.4, -0.3) -0.16 (-0.19, -0.14) 
    No charge/other  -0.3 (-0.3, -0.3) -0.17 (-0.19, -0.16) 
Neighborhood median household income    
    Bottom quartile  - - 
    Second quartile  0.0 (0.0, 0.0) -0.01 (-0.01, 0.00) 
    Third quartile  -0.1 (-0.1, 0.0) -0.02 (-0.03, -0.01) 
    Top quartile  -0.1 (-0.1, -0.1) -0.03 (-0.04, -0.03) 
Patient urban-rural classification    
    Counties <249,999 - - 
    Counties 250,000-999,999  0.0 (0.0, 0.1) 0.02 (0.01, 0.03) 
    Fringe counties, ≥1 million 0.1 (0.1, 0.2) 0.06 (0.05, 0.07) 




Hospital ownership      
    Private, investor-owned  - - 
    Private, not-for-profit  0.0 (0.0, 0.0) 0.01 (0.00, 0.02) 
    Government, non-federal  0.2 (0.1, 0.2) 0.07 (0.06, 0.08) 
Hospital size      
    Small  - - 
    Medium  0.1 (0.1, 0.1) 0.05 (0.04, 0.06) 
    Large  0.2 (0.2, 0.2) 0.10 (0.09, 0.11) 
Hospital teaching status     
    Urban, non-teaching  - - 
    Non-metropolitan 0.0 (0.0, 0.0) 0.01 (0.00, 0.02) 
    Urban, teaching  0.1 (0.1, 0.1) 0.05 (0.05, 0.06) 
Year      
    2012 - - 
    2013 0.0 (-0.1, 0.0) -0.01 (-0.02, 0.00) 
    2014 0.0 (-0.1, 0.0) -0.02 (-0.03, -0.01) 
    2015 -0.1 (-0.1, 0.0) -0.02 (-0.03, -0.02) 
    2016 -0.1 (-0.1, -0.1) -0.04 (-0.05, -0.03) 
Notes:  
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).  
(ii) Average marginal effects (AME; in number for total number of admissions, and in probability for any unplanned readmissions) 





Table 9.  Total costs, inpatient days, number of admissions, and probability of any 
unplanned readmission among total study population and stratified by treatment 
strategy:  January as index admission and 11-month follow-up (n = 32,750). 
  Total study SAVR  TAVR  MT  P-value  
 population          
  (n = 32,246) (n =10,040) (n = 2,892) (n = 19,314)    
Total costs, mean (SD)            
    All admissions  41,566 (46,648) 60,759 (56,359) 67,676 (40,874) 27,704 (35,091)   < 0.01 
    Index admission only  29,486 (36,481) 53,474 (47,223) 56,681 (29,291) 12,921 (15,326)   < 0.01 
    Readmissions only  12,081 (28,229) 7,285 (25,436) 10,996 (24,361) 14,784 (29,756)   < 0.01 
Inpatient days, mean (SD)            
    All admissions  11.9 (12.9) 12.2 (12.8) 11.3 (12.9) 11.7 (12.9)   < 0.01 
    Index admission only  6.8 (6.6) 9.6 (8.5) 6.8 (6.8) 5.3 (4.7)   < 0.01 
    Readmissions only  5.1 (10.5) 2.6 (7.9) 4.5 (9.5) 6.4 (11.5)   < 0.01 
Admissions, mean (SD)            
    Number of all admissions  1.9 (1.4) 1.4 (0.9) 1.7 (1.3) 2.1 (1.5)   < 0.01 
    Probability of any readmission  0.44 (0.50) 0.27 (0.44) 0.40 (0.49) 0.53 (0.50)   < 0.01 
Notes:  
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).  
(ii) Mean and standard deviation (SD) were adjusted for HCUP-NRD discharge weights to generate nationally representative 




Table 10.  Association of treatment strategy with total charges:  total charges during all 
admissions, index admission only, and readmissions only (n = 190,563). 
  All admissions  Index admission only  Readmissions only  
  AME in $ (95% CI)  AME in $ (95% CI)  AME in $ (95% CI)  
Treatment strategy        
    SAVR  - - - 
    TAVR  31270 (27915, 34625) 21617 (19305, 23929) 17076 (15415, 18737) 
    MT  -87112 (-89259, -84964) -96897 (-98205, -95590) 16321 (15213, 17429) 
Age category        
    64 - - - 
    65-74  -21738 (-25240, -18237) -4961 (-7051, -2870) -13283 (-15514, -11053) 
    75-84 -29995 (-33523, -26467) -8573 (-10683, -6463) -15993 (-18201, -13785) 
    85 -44772 (-48419, -41125) -15820 (-18033, -13607) -20292 (-22503, -18082) 
Women  -299 (-1748, 1149) -1488 (-2397, -578) 743 (-2, 1487) 
Charlson comorbidity index        
    0-1 - - - 
    2-3 20377 (18597, 22158) 6051 (4924, 7178) 10928 (10045, 11811) 
    4-5 35410 (33092, 37728) 13962 (12554, 15369) 16721 (15587, 17856) 
    6 33920 (30583, 37257) 24215 (22093, 26338) 14252 (12650, 15854) 
Number of inpatient procedures        
    0 - - - 
    1-2 65615 (64118, 67112) 35287 (34488, 36085) 21201 (20352, 22051) 
    3-4 91037 (89099, 92975) 65769 (64791, 66747) 20136 (18903, 21370) 
    5 123391 (121119, 125663) 120131 (118780, 121482) 11995 (10476, 13514) 
Severity of illness        
    Minor loss of function  - - - 
    Moderate loss of function  22632 (20073, 25190) 3913 (2010, 5816) 10772 (9339, 12205) 
    Major loss of function  36482 (33565, 39400) 18175 (16031, 20318) 13282 (11682, 14883) 
    Extreme loss of function  29339 (25521, 33157) 37867 (34834, 40899) -13805 (-15541, -12069) 
Risk of mortality        
    Minor likelihood of dying - - - 
    Moderate likelihood of dying 19919 (17754, 22084) 2862 (1382, 4342) 11799 (10555, 13043) 
    Major likelihood of dying 29040 (26306, 31773) 13929 (12103, 15756) 12481 (11000, 13963) 
    Extreme likelihood of dying 46425 (41765, 51084) 44181 (40779, 47582) -502 (-2622, 1618) 
Insurance status        
    Medicare  - - - 
    Medicaid  12874 (7372, 18377) 8569 (5228, 11910) 3029 (244, 5815) 
    Private  -27208 (-29715, -24702) -5150 (-6946, -3354) -14652 (-15843, -13461) 
    Self-pay  -33036 (-40128, -25943) -1616 (-8188, 4957) -19757 (-22282, -17231) 
    No charge/other  -24453 (-29901, -19006) 3660 (-697, 8018) -18948 (-20990, -16906) 
Neighborhood median household income      
    Bottom quartile  - - - 
    Second quartile  -3388 (-5434, -1342) -476 (-1724, 772) -1244 (-2316, -173) 
    Third quartile  -4955 (-7075, -2835) 1017 (-295, 2329) -2752 (-3826, -1678) 
    Top quartile  1645 (-608, 3897) 7984 (6576, 9392) -1860 (-3037, -682) 
Patient urban-rural classification    - 
    Counties <249,999 - - - 
    Counties 250,000-999,999  14521 (12562, 16479) 8916 (7623, 10208) 4977 (4021, 5934) 
    Fringe counties, ≥1 million 24140 (21956, 26323) 10999 (9633, 12365) 10133 (9057, 11208) 




Hospital ownership        
    Private, investor-owned  - - - 
    Private, not-for-profit  -74998 (-78052, -71944) -63610 (-65459, -61761) -12746 (-14292, -11200) 
    Government, non-federal  -53847 (-57792, -49902) -57535 (-59827, -55244) -3288 (-5256, -1319) 
Hospital size        
    Small  - - - 
    Medium  25879 (23537, 28220) 15377 (13824, 16929) 6920 (5918, 7922) 
    Large  56194 (54081, 58307) 31141 (29732, 32551) 18387 (17443, 19331) 
Hospital teaching status       
    Urban, non-teaching  - - - 
    Non-metropolitan -39200 (-41946, -36453) -32480 (-34283, -30678) -5912 (-7169, -4655) 
    Urban, teaching  6731 (5025, 8436) -4641 (-5743, -3538) 6108 (5272, 6944) 
Year        
    2012 - - - 
    2013 -1203 (-3798, 1392) 1559 (-29, 3147) -2465 (-3783, -1147) 
    2014 -4776 (-7282, -2271) -659 (-2183, 866) -3379 (-4712, -2046) 
    2015 1279 (-1205, 3762) 5138 (3619, 6658) -2566 (-3881, -1252) 
    2016 519 (-1923, 2960) 7334 (5812, 8856) -3814 (-5116, -2512) 
Notes:  
(i) SAVR (surgical aortic valve replacement), TAVR (transcatether aortic valve replacement), MT (medical therapy).  
(ii) Average marginal effects (AME; $) and 95% confidence interval (CI) were adjusted for HCUP-NRD discharge weights to 





CHAPTER 4:  DISCUSSION 
TAVR Increasing 
In nationally-representative sample of 366,909 patients hospitalized for aortic 
valve disease, IA increased 48.1% from 2012 through 2016.  The likelihood of receiving 
TAVR increased with an RRR of 4.57 relative to SAVR and 4.41 relative to MT, a novel 
finding.  However, not all patients and hospitals absorbed TAVR equally:  increasing 
age, female sex, severity of illness rating, high number of diagnoses, not-for-profit 
hospital ownership, large hospital size, and teaching hospital status were associated 
with a higher prevalence of TAVR.   
Increasing patient age was associated with increased use of TAVR and 
decreased use of SAVR.  The potential for future growth in TAVR remains enormous 
due to the high prevalence of aortic valve disease in elderly patients, the overall aging of 
the US population, and anticipated expansion of TAVR to low-surgical risk patients.  
Thus, from a public health perspective, knowledge of trends in aortic valve disease is 
necessary to ensure adequate allocation of medical and financial resources to care for 
the ever-increasing number of aortic valve patients.  Our study showed a 5-year 
increase of 48.1% in patients hospitalized for aortic valve disease, likely reflecting both 
the aging of the population and the increased availability of TAVR.  A 2013 meta-
analysis of 7 studies including 9,723 patients reported a prevalence of AS of 12.4% in 
patients aged ≥75 years including 3.4% with severe AS35.  A 2017 meta-analysis of 56 
studies in 37 countries including 42,965 patients reported the prevalence of AS to be 
4.5%, comprised of 2.8% (95% CI 1.4-4.1%) of patients aged 60-74 years and 13.1% 
(95% CI 8.2-17.9%) of patients aged >75 years; 19.9% (95% CI 12.8-26.9%) of AS was 
classified as severe, corresponding to an estimated 781,773 (95% CI 542,923-
1,063,142) patients in the US, and >40% of patients did not undergo any sort valve 




Increasing severity of illness was associated with a preference for TAVR over 
SAVR.  The evidence supporting this practice is historical:  the pivotal randomized 
controlled trials comparing mortality following TAVR and SAVR showed equipoise for 
intermediate-risk patients5,6,37; for high-risk patients, the trials diverged with one showing 
equipoise3 and another showing TAVR to be superior4.  Recent data regarding low-risk 
patients38,39 will likely lead to a future increase in TAVR and decrease in SAVR in this 
patient population.   
 
Inequitable Distribution 
Patients treated at large hospitals and urban teaching hospitals were more likely 
to undergo valve replacement than patients treated at small hospitals, urban non-
teaching hospitals, and rural hospitals; hospitals categorized as not-for-profit and 
government, non-federal were more likely to provide TAVR but not SAVR than for-profit 
private hospitals.  As new data and procedural techniques emerge rapidly, they are 
incorporated into clinical practice unequally between different types of hospitals:  in our 
study, the rates of increase in TAVR and decrease in both SAVR and MT confirm that 
large urban teaching not-for-profit hospitals are far faster to adopt novel evidence-based 
practices for the treatment of aortic valve disease than their small, rural, non-teaching, or 
for-profit counterparts.  Trends in the care of patients with aortic valve disease require 
much more research at the national level.  Factors limiting access to TAVR must be 
identified and rectified.   
 
Cost and Cost Effectiveness 
 Among 190,563 patients with significant aortic valve disease treated from 2012-
2016, the average 6-month inpatient costs were $59,743 for SAVR, $64,395 for TAVR, 




provide a survival benefit over MT for patients with severe aortic stenosis2,40, the 6-
month costs of either intervention clearly exceed the cost of MT.   
 In aggregate, the costs of SAVR, TAVR, and MT are estimated to total a 
combined $10.2 billion annually in the US41.  Several prior studies have examined the 
costs of aortic valve disease care in selected populations.  In the PARTNER trial cohort 
B of inoperable patients randomized to TAVR or MT, TAVR carried a higher cost for the 
initial hospitalization ($78,542 versus $42,806 respectively), but MT resulted in follow-up 
costs almost twice those of TAVR ($29,289 versus. $53,621 respectively)42.  In 2012, 
Medicare payments for the 4083 beneficiaries undergoing TAVR totaled $215,770,200, 
or a median of $49,500 (interquartile range [IQR] $36,900-64,600) per hospitalization, 
barely less than the $50,400 (IQR $37,400-65,800) for propensity-matched SAVR 
patients (p<0.01)43.  Notably, for intermediate-risk trial patients, TAVR incurred ≈$20,000 
more than SAVR in procedural costs but $11,377 less (p<0.01) in 2-year follow-up 
costs44.   
 Across several studies, TAVR has been associated with increased procedural 
costs but decreased post-procedural resource utilization in comparison to SAVR; cost 
effectiveness estimates vary widely, particularly as a result of varying costs in different 
healthcare systems13.  Indeed, assessing cost effectiveness is much more complicated 
than simply reporting raw costs.  The American College of Cardiology typically defines 
high value interventions as costing <$50,000 per quality-adjusted life year (QALY)45.  
While our study was not able to assess quality of life, we were able to report from our 
sensitivity analysis that, compared with MT, 11-month costs among all admissions were 
$33,055 more for SAVR and $39,972 more for TAVR (Appendix Table 1, p<0.01).  While 
either valve replacement modality carries higher-up front costs than MT, as MT is 
increasingly reserved for only higher-risk patients, their frequent readmissions and on-




 Previous studies have yielded highly variable findings regarding cost 
effectiveness.  A 2018 hypothetical cost-effectiveness model for intermediate risk 
patients in the Canadian healthcare system suggested that TAVR added 0.23 QALYs 
versus SAVR at an incremental cost of $46,083 Canadian per QALY46.  Conversely, a 
2013 hypothetical cost effectiveness analysis for inoperable patients receiving TAVR 
versus MT estimated an increase in quality-adjusted life expectancy from 1.19 to 1.93 
years at an incremental cost of $99,900 per QALY47.  A 2014 Spanish cost-utility 
analysis of 207 high-risk patients reported a significant improvement in the cost-
effectiveness of TAVR when the price of TAVR devices was reduced by 30%, 
highlighting the important role of this single expense in the economics of TAVR48. 
  
Inpatient Duration and Readmission 
We found that the average numbers of inpatient days across all admissions over 
a 6-month period beginning with IA were 12.1 for SAVR, 10.0 for TAVR, and 9.7 for MT, 
and the average number of admissions were 1.3, 1.5, and 1.7 respectively.  In our first 
sensitivity analysis, when we extended the follow-up period to 11 months, we observed 
similar results to the main 6-month analysis.  Long-term data are lacking, and further 
studies must test the hypothesis that the up-front costs of SAVR and TAVR are offset by 
reduced numbers of duration of subsequent readmissions, potentially making valve 
replacement increasingly cost effective in comparison to MT over several years.  Also, 
as TAVR operators adopt minimalist practices and short hospital stays, TAVR has 
become less expensive and could become even less expensive than SAVR.  Arguing 
against these hypotheses, an analysis of the National Cardiovascular Data Registry 
(NCDR) Transcatheter Valve Therapies (TVT) Registry found an increase in all-cause 
hospitalization and inpatient days in the 1 year post-TAVR compared with the 1 year pre-




hospitalizations increased even more49.  However, when excluding the cost of the TAVR 
admission, inpatient costs were slightly lower in the post-TAVR year than the pre-TAVR 
year.   
 
A Field in Economic Flux 
From a health systems perspective, an understanding of the costs, inpatient 
days, and readmission rates associated with different aortic valve disease management 
strategies is necessary to ensure that resources are appropriately apportioned to provide 
care for the increasing number of aortic valve disease patients.  TAVR continues to 
supplant both SAVR and MT1, and the future growth potential for aortic valve therapy is 
enormous given the high prevalence of aortic valve disease:  aortic stenosis is present in 
up to 4.5% of the population in developed countries with 19.9% classified as severe, and 
>40% go without valve replacement36.  Additionally, AR patients may also receive SAVR, 
TAVR, or MT.   
The field of aortic valve disease is in great flux at present with the continued 
expansion of TAVR, and many changes in the economics of aortic valve disease can be 
expected.  For example, in our study, a greater percentage of TAVR patients than SAVR 
or MT patients were treated in hospitals characterized as large, not-for-profit, urban 
teaching, and in affluent neighborhoods, characteristics associated with more expensive 
hospitalizations in general50.   While we controlled for disparities in many hospital 
characteristics in our estimation of costs, the profile of TAVR-capable hospitals is rapidly 
changing in light of an updated National Coverage Determination by the Center for 
Medicare and Medicaid Services that significantly reduced the requirements for hospitals 
to perform TAVR51.   
During our 5-year study period, IA costs and days decreased over time for TAVR 




progressively lower risk profile of TAVR patients.  However, even at the end of the study 
period, TAVR was only available for patients at intermediate or greater surgical risk, with 
intermediate risk approval occurring on August 18, 2016.  Given this greater severity of 
illness among TAVR vs. SAVR patients, we did find more readmission inpatient days 
and higher readmission rates with TAVR.  Looking specifically toward intermediate 
surgical risk patients, among patients with minor or moderate loss of function, IA was 
more expensive for TAVR that for SAVR:  we may conjecture that the increased costs 
relate to the higher cost of the TAVR prosthesis than the SAVR prosthesis.   
 The approval of TAVR for patients at low surgical risk52 will further alter the 
economics of aortic valve disease.  Additionally, the economic landscape may continue 
to change with the results of the on-going EARLY TAVR trial (NCT03042104) studying 
TAVR in severe, asymptomatic aortic stenosis and the TAVR UNLOAD trial studying 
TAVR in moderate aortic stenosis (NCT02661451).  Fortunately, thanks to the 
availability of the HCUP NRD, this analysis may be repeated with relative ease in to 
update the assessment of SAVR, TAVR, and MT costs in the future.   
 
Strengths and Limitations 
Prior studies have examined the use and economics of SAVR and TAVR, but our 
novel study also includes the population treated with MT.  Furthermore, our unique 
January-through-June study methodology allowed us to obtain 6-months of post-
discharge follow-up data for hundreds of thousands of patients with admissions for aortic 
valve disease undergoing valve replacement or symptomatic with CHF, UA, NSTEMI, 
and/or syncope.  In contrast, most previous studies of aortic valve disease in HCUP data 
have employed the NIS, which does not provide unique patient identifiers, thus rendering 




examine outcomes per discharge, whereas our NRD methodology allowed 6-month 
follow-up on a per-patient basis, a more relevant measure for SAVR, TAVR, and MT. 
 Our study methodology has several important limitations.  First, ICD-9-CM codes 
do not permit differentiation between AS and AR.  The prevalence of moderate or severe 
AR is only approximately 0.5%56, and AR therapy has changed minimally with the advent 
of TAVR, so AR is unlikely to have contributed to the trends in therapy observed in this 
study:  the trends observed in this study are principally attributable to AS therapy.   
Second, neither ICD-9-CM nor ICD-10-CM codes quantify the severity of aortic 
valve dysfunction.  Most patients with non-severe valve disease do not undergo valve 
replacement unless SAVR is performed for moderate AS or AR at the time of another 
cardiac surgery, typically coronary artery bypass grafting.  Thus, we recognize the bias 
that patients with less severe valvular disease will generally be classified in the MT 
group.  To mitigate this bias, we restricted our primary analysis to patients with a 
concomitant diagnosis suggesting significant AS or AR (i.e., SAVR, TAVR, CHF, UA, 
NSTEMI, and syncope):  as seen in the first therapy trends sensitivity analysis, this 
concomitant diagnosis eliminated 244,432 patients, 98.4% of whom received medical 
therapy, suggesting that non-severe aortic valve disease was present.  Of course, billing 
codes cannot determine precisely what fraction of patients hospitalized for aortic valve 
disease specifically had severe aortic stenosis, the only FDA-approved indication for 
TAVR.  Still, indications will change:  the PARTNER 338 and Evolut Low Risk39 trials 
demonstrated safety and efficacy of TAVR in low-surgical-risk patient; the on-going 
EARLY TAVR trial (NCT03042104) is studying TAVR in severe, asymptomatic aortic 
stenosis; and the on-going TAVR UNLOAD trial is studying TAVR in moderate aortic 
stenosis (NCT02661451).  Ultimately, we believe that, because all included patients had 




as billing diagnoses for hospital admission, the patient populations in the SAVR, TAVR, 
and MT groups were adequately comparable for a meaningful analysis.   
Third, the NRD only captures inpatient data, excluding outpatient, emergency 
department, and observation visits, which may contribute to overall costs.   
Fourth, the NRD does not capture vital status after discharge, so the competing 
risk of death may influence our observed readmission data.   
Fifth, our main analyses used six months of follow-up, and some patients who 
received MT during the study period may have subsequently undergone SAVR or TAVR, 
although results did not change appreciably in the sensitivity analyses looking at follow-
up to 11 months.  Indeed, the population in the cost analysis was smaller than the 
population in the therapy trends analysis because the cost analysis excluded from the 
MT group patients who underwent SAVR or TAVR any time during the calendar year, 
even after 6 months of follow-up.  The rare patients undergoing balloon aortic 
valvuloplasty would also be categorized as receiving MT, but this seems appropriate 
given the short duration of effect of this procedure.  Conclusively, despite these 
limitations, this study provides important and novel information regarding the variation in 
use of SAVR, TAVR, and MT in the US. 
 
Conclusions 
From 2012 through 2016, the use of TAVR increased at the expense of both 
SAVR and MT.  The greatest use of TAVR was associated with patients at elevated 
surgical risk and hospitals that were large, not-for-profit, and urban teaching hospitals.  
Expected expansion of TAVR indications portends continued growth of TAVR and 
reduction in SAVR and MT.  The inequitable distribution of TAVR therapy must be 




 For patients admitted with aortic valve disease, 6-month inpatient costs were 
higher for treatment with TAVR than for treatment with SAVR, and both valve 
replacement modalities were significantly more expensive than MT.  Compared to 
SAVR, IA was shorter for TAVR and MT, but 6-month readmission inpatient days and 
the likelihood of readmission were greater for TAVR and MT.  IA costs and days 
decreased over time for TAVR but remained stable for SAVR and MT.  The relative cost 
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